Upregulation of the receptor tyrosine kinase MET has been described in DMS114 lung cancer cells (FGFR1 amplified), made resistant to infigratinib[50] and H1581 lung cancer cells (FGFR1 amplified) made resistant to AZD4547 and the FGFR inhibitor rogaratinib[51]. This evidence concerns the gene MET and lung cancer.